Inotiv, Inc. (NOTV)

In the past six months, Inotiv, Inc.'s stock price has significantly declined. As of April 7, 2026, the share price was $0.25, an 89.56% decrease from April 8, 2025. Key events impacting the stock include the Q4 FY2025 and FY2025 financial results, which showed revenue increases but also the sale of properties to repay debt. The Q1 FY2026 financial results revealed increased DSA revenue but headwinds in the RMS business. A cybersecurity incident was disclosed in August 2025. Historically, NOTV shares have tended to decline after earnings reports.

Specific demand seasonality for Inotiv, Inc.'s products and services is not explicitly detailed. The Q1 FY2026 earnings call mentioned seasonal weakness in the RMS business. Historically, July has shown the highest probability of positive returns for NOTV stock, while August has the lowest.

Inotiv, Inc. is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services. The company operates in the Pharmaceuticals & Biotech sector, focusing on Life Sciences Tools and Services. Inotiv's services support the discovery and preclinical phases of drug and medical device development, aiming to enhance efficiency, improve data quality, and reduce costs. It operates through two segments: Discovery and Safety Assessment (DSA), which provides services for drug candidates, biotherapeutics, and biomedical devices, and Research Models and Services (RMS), which offers research models and related services.

Inotiv has a global presence with over 2,000 employees across more than 22 locations in North America and Europe. The company's headquarters are located in West Lafayette, Indiana, United States.

In the past year, Inotiv's brand reputation has been impacted by a criminal investigation related to its canine breeding facility, resolved through agreements with the DOJ and USAO-WDV. A cybersecurity incident in August 2025 could also affect its reputation. However, Inotiv was ranked 182nd on the 2025 Deloitte Technology Fast 500™, highlighting significant revenue growth due to strategic acquisitions and a client-focused CRO model.

Inotiv, Inc. has a diverse ownership structure, including institutional, insider, and retail investors. As of April 2025, institutional investors held about 26.84% of shares, while insider ownership was around 30.47% in April 2025, decreasing to 9.15% by August 2025. Major institutional owners include Balyasny Asset Management Llc, Vanguard Group Inc, and Gsa Capital Partners Llp. Significant individual owners include P2 Capital Partners LLC, John E. Sagartz, and Robert W. Leasure, Jr.